pharmaphorum December 22, 2025
Nine more pharma groups have agreed to lower the costs of their medicines in the US under the Trump administration’s most favoured nation (MFN) scheme in return for avoiding tariffs.
US companies Amgen, Bristol Myers Squibb, Gilead Sciences, and Merck/MSD have signed up to reduce the prices of medicines for Medicare and cash buyers through the TrumpRx direct-to-consumer (DTC) sales channel, along with Roche’s Genentech unit, with European firms Boehringer Ingelheim, GSK, Novartis, and Sanofi also agreeing terms.
Under the MFN policy, Trump is attempting to bring medicine prices in line with those paid in other developed nations.
The new sign-ups join AstraZeneca, Eli Lilly, Merck KGaA, Novo Nordisk, and Pfizer, which also agreed MFN deals in recent weeks to...
Today's Sponsors
Today's Sponsor